Clover Biopharmaceuticals Issues Supplemental Announcement on Model Code Compliance
Key Highlights for Investors
- Clover Biopharmaceuticals, Ltd. (“the Company”) has released supplemental information regarding compliance with the Model Code for Securities Transactions by Directors of Listed Issuers (“Model Code”).
- This follows disclosures in the 2025 Annual Results Announcement and Annual Report, addressing recent compliance concerns.
- The Company is implementing enhanced measures to reinforce adherence to share trading compliance among its Grantors and insiders.
Details of the Announcement
Clover Biopharmaceuticals has provided further clarification regarding compliance procedures surrounding the Model Code, following issues noted in its 2025 annual disclosures. The Company recognizes the critical importance of strict adherence to the Model Code to protect shareholder interests and maintain transparency in the market.
To prevent any recurrence of non-compliance incidents, the Company has taken the following actions:
- Explicitly reminded all Grantors (i.e., persons granted share options or awards) of the need for strict compliance with the Model Code when dealing in the Company’s shares.
- Circulated updated share trading compliance guidelines to these individuals, reiterating the compliance procedures required for share transactions.
Additionally, the Company will strengthen internal controls and monitoring of securities transactions by implementing the following measures:
- Advanced Notification of Blackout Periods: All Grantors will be notified of blackout period schedules before they commence, reducing the risk of inadvertent breaches of trading restrictions.
- Pre-Trade Approval: Grantors must notify Dr. Peng Liang (Chairman of the Board) and the Company before executing any share transaction, and may only proceed after receiving explicit confirmation from Dr. Liang.
- Post-Trade Reporting: Grantors are required to report any completed share transaction to Dr. Liang and the Company within one day of execution.
- Quarterly Compliance Refresh: The Company will conduct quarterly sessions to reinforce the requirements of the Model Code and disclosure of interest regime, ensuring ongoing awareness among Grantors.
- Quarterly Compliance Meetings: A scheduled Teams meeting each quarter will bring together Dr. Liang, the Grantors, and the Company’s Joint Company Secretary to discuss potential share dealings and review compliance matters.
It is important to note that, apart from the above supplementary measures, all other content from the previous Annual Results Announcement and Annual Report remains unchanged.
Why This Matters to Shareholders
- Investor Confidence & Market Transparency: These enhanced measures are aimed at reinforcing investor confidence in the Company’s governance and transparency regarding insider transactions.
- Potential Price Sensitivity: Any public perception of improved or inadequate compliance practices could impact the Company’s reputation and, potentially, its share price. The Company’s proactive steps may be viewed positively by the market.
- Regulatory Compliance: These efforts signal a commitment to best practices, which is crucial in maintaining a positive relationship with regulators and the investing public.
Board Composition (as of June 5, 2026)
- Chairman & Executive Director: Dr. Peng Liang
- Executive Director: Mr. Joshua G. Liang
- Non-Executive Directors: Dr. Xiaodong Wang, Dr. Donna Marie Ambrosino
- Independent Non-Executive Directors: Dr. Xiaobin Wu, Mr. Xiang Liao, Mr. Jeffrey Farrow, Mr. Thomas Leggett
Conclusion
The Company’s supplementary measures to reinforce Model Code compliance, along with regular internal reviews and communication, are crucial steps to mitigate future risks and enhance corporate governance. Shareholders should monitor how these initiatives are implemented and whether they result in sustained improvements in compliance culture.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to review official Company filings and consult with their financial advisors before making investment decisions.
